STOCK TITAN

Karuna Therapeutics, Inc. - $KRTX STOCK NEWS

Welcome to our dedicated page for Karuna Therapeutics news (Ticker: $KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Karuna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Karuna Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.18%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
conferences
Karuna Therapeutics, Inc.

Nasdaq:KRTX

KRTX Rankings

KRTX Stock Data

12.60B
36.27M
4.99%
86.32%
5.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About KRTX

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip